ASH Impact Series: Sagar Lonial, MD - Examining Multiple Myeloma Drug Combination Treatments
ASH Impact Series: Sagar Lonial, MD - Treating Newly Diagnosed Multiple MyelomaПодробнее
Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее
Dr. Sagar Lonial on Lenalidomide Versus Observation in Smoldering MyelomaПодробнее
ASH Impact Series: Vincent Rajkumar, MD - Examining the New FDA Approved Myeloma Drug ProductsПодробнее
Prof. Sagar Lonial | ASH 2017 | Highlights of ASH in RRMMПодробнее
Sagar Lonial, MD, FACP, Talks Multiple Myeloma Highlights from the Summer ConferencesПодробнее
ASH Impact Series: Paul Richardson, MD - Examining the New FDA Approved Myeloma Drug ProductsПодробнее
Dr. Lonial Discusses Novel Agents in Multiple MyelomaПодробнее
Dr. Sagar Lonial on Understanding Multiple MyelomaПодробнее
Dr. Lonial on Differentiating Patients With Smoldering and Multiple MyelomaПодробнее
Rise of antibody-based treatments in myelomaПодробнее
Sagar Lonial discusses his top myeloma research picksПодробнее
The antibody treatment landscape in myelomaПодробнее
IMS Highlights for Triple Class Refractory Myeloma | Sagar Lonial, MD, FACP | IMS 2023Подробнее
Sagar Lonial, MD on elotuzumab for mutliple myeloma patientsПодробнее
Dr. Lonial on Novel Mechanisms in Multiple MyelomaПодробнее
Phase III trial of lenalidomide vs observation alone in pts with asymptomatic high-risk SMMПодробнее
Dr. Sagar Lonial on Treating Patients With Smoldering Multiple MyelomaПодробнее
Sagar Lonial, MD, FACP, on Multiple Myeloma Awareness MonthПодробнее
